
Real-World Brexu-cel Results in MCL Mirror Trials; Cost, QOL Data Lag
Key Takeaways
- Pooled real-world MCL outcomes showed 88% overall response and 76% complete response, with median OS 40.3 months and PFS 18.3 months, approximating but underperforming ZUMA-2.
- Safety signals were consistent with trials, with grade ≥3 CRS/ICANS of 12%/20% in MCL and 10%/21% in B-ALL, potentially influenced by earlier tocilizumab/steroid use.
Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.
Nearly 9 in 10 patients with relapsed or refractory
Brexu-cel Trial Data Left Real-World Questions Open
Brexu-cel, a CD19-directed CAR T-cell therapy, is used in adults with relapsed or refractory MCL and relapsed or refractory B-cell
Although the effectiveness and safety evidence for brexu-cel is well established, the review authors noted that real-world evidence on health care resource use (HCRU), costs, and health-related quality of life (HRQOL) had remained limited, and no systematic review had synthesized it.1 The review aimed to fill that gap in both diseases.
31 Real-World Cohorts Pooled Across the US and Europe
The researchers searched Embase, MEDLINE, and CENTRAL for observational studies of adults with relapsed or refractory MCL or B-ALL treated with brexu-cel, with clinical searches updated in March 2025. They identified 69 publications representing 31 real-world cohorts, most from the US (n = 20) or Europe (n = 10), plus 1 international cohort.
Effectiveness and safety were pooled by meta-analysis, with survival estimated from patient-level data reconstructed from published curves; HCRU, cost, and HRQOL findings were summarized descriptively. Prior BTK inhibitor exposure in the MCL cohorts was 76.2% to 95.0%, and median follow-up was 4.2 to 25.6 months.
Responses in MCL Held Up Outside of Trials
In MCL, the pooled overall response rate was 88% (95% CI, 85%-91%), and the complete response rate was 76% (95% CI, 68%-82%). Median overall survival (OS) was 40.3 months (95% CI, 36.2-45.8). Median progression-free survival (PFS) was 18.3 months, and median duration of response was 19.9 months, compared with a median OS of 46.6 months and median PFS of 25.8 months reported for ZUMA-2.
In B-ALL, pooled complete response and measurable residual disease negativity rates were 74% and 73%, respectively, and median OS was 23.3 months, though the authors cautioned that these data were of limited maturity. ZUMA-3 (NCT02614066) reported a median OS of 18.2 months.
CRS and immune effector cell–associated neurotoxicity syndrome (ICANS) were the most common adverse events. In MCL, grade 3 or higher CRS and ICANS occurred in 12% and 20% of patients, versus 15% for CRS and 31% for neurologic events in ZUMA-2. In B-ALL, the corresponding rates were 10% and 21% vs 25% and 24% in ZUMA-3.
The authors suggested the lower rates of severe events may reflect greater and earlier use of tocilizumab and corticosteroids, which 77% and 61% of patients with MCL received, respectively. ICANS had not yet been defined when the pivotal trials ran, and retrospective documentation may also underestimate adverse events.
Cost and Quality-of-Life Evidence Remains Thin
Median hospital stays ran 15 to 22 days, and 11% to 34% of patients in MCL cohorts were admitted to intensive care. Only 1 real-world cost study was identified, an MCL analysis of
"The complete absence of real-world HRQoL evidence represents a critical gap," the authors wrote. "With brexu-cel now delivering durable remissions, generating patient-centered data in routine care is a pressing priority for future research to more fully characterize its value beyond survival and safety."
Retrospective Designs and Industry Funding Temper Conclusions
The researchers acknowledged that the cohorts were largely retrospective, with a risk of bias and inconsistent reporting that left limited data for some end points. Survival estimates depended on curve reconstruction, and short follow-up in some cohorts may have missed late relapses or toxicities. The study was funded by Kite, a Gilead Company, which markets brexu-cel, and several authors are affiliated with Kite.
For managed care decision-makers, the findings suggest brexu-cel's clinical benefit carries over to routine practice, but the lack of real-world economic and patient-reported data restricts a full value assessment. The authors called for better data to inform reimbursement decisions and care pathways for a one-time therapy with durable responses.
References
- Shah BD, Iloabuchi C, Harrigan S, et al. Clinical, economic, and quality-of-life outcomes of brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma and B-cell acute lymphoblastic leukemia: a systematic literature review and meta-analysis. J Manag Care Spec Pharm. 2026;32(10):1296-1310. doi:10.18553/jmcp.2026.32.10.1296
- Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347
Related to this article








